Entrada CFO sells 2,500 TRDA shares at $12.95

Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction.

Rhea-AI Filing Summary

Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 2,500 shares of Common Stock in an open-market transaction. The sale occurred at a price of $12.95 per share. After the trade, he directly holds 119,010 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025, indicating it was pre-scheduled.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider WENTWORTH KORY JAMES

Role Chief Financial Officer

Sold 2,500 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$12.95	$32K

Holdings After Transaction: Common Stock — 119,010 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

Key Figures

Shares sold: 2,500 shares Sale price: $12.95 per share Shares held after sale: 119,010 shares +1 more

4 metrics

Shares sold 2,500 shares Open-market sale of Common Stock on April 1, 2026

Sale price $12.95 per share Price for the 2,500 Common Stock shares sold

Shares held after sale 119,010 shares Direct ownership following the reported transaction

Trading plan adoption date March 6, 2025 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entrada Therapeutics (TRDA) report in this Form 4?

Entrada Therapeutics reported that its Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of Common Stock. The sale was an open-market transaction at $12.95 per share and was carried out under a pre-arranged Rule 10b5-1 trading plan.

How many Entrada Therapeutics (TRDA) shares did the CFO retain after the sale?

After selling 2,500 shares, the CFO directly holds 119,010 shares of Entrada Therapeutics Common Stock. This shows that the reported transaction represents a small portion of his overall position, with the majority of his holdings remaining invested in the company.

At what price were the Entrada Therapeutics (TRDA) shares sold in the Form 4 filing?

The reported shares were sold at a price of $12.95 per share. This per-share sale price comes from an open-market transaction disclosed for 2,500 shares of Entrada Therapeutics Common Stock executed by the company’s Chief Financial Officer.

Was the Entrada Therapeutics (TRDA) CFO’s share sale part of a Rule 10b5-1 plan?

Yes, the CFO’s sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading activity from non-public information and making the timing more routine.

Who is the insider involved in the latest Entrada Therapeutics (TRDA) Form 4?

The insider is Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics. He reported an open-market sale of 2,500 shares of Common Stock at $12.95 per share and now directly owns 119,010 shares following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		2,500	D	$12.95	119,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)